JAK2 and neoplasm: The JAK2/STAT3 pathway is an important driver of tumor progression, immune evasion, and therapy resistance (Figure 3); persistent STAT3 activation is linked to poor prognosis in multiple malignancies, including esophageal, breast, and colorectal cancer (Jia et al. 2021).